Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan

Citations Over TimeTop 18% of 2021 papers

Abstract

Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2-64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan-Meier analysis, which revealed that the median survival durations were 49 (9-88) and 25 (8-41) months in the edaravone and control groups, respectively (p = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS.

Related Papers

• → Sustained Efficacy for up to 12 Months in an Active Extension of a Phase III Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS) (P3.190)(2016)1 cited
• AN SURVIVAL ANALYSIS OF STOMACH CANCER IN FUZHOU(2003)
• → [Long-term clinical evaluation of different types of resin-bonded fixed partial denture to replace lost anterior teeth].(2023)2 cited
• The survival analysis of patients with digestive cancer(2012)
• Survival Analysis After Kassi Operation For Patients With Biliary Atresia.(2005)